Dyadic International shares rise 14.96% intraday after establishing commercial partnership with Opes Diagnostics for recombinant human product launch.

Dyadic International surged 14.96% intraday after announcing a commercial partnership with Opes Diagnostics to support the launch of its recombinant human product. The agreement, involving Dyadic's Applied BioSolutions division, signals expanded market access for the company's biotechnology innovations, positioning it to capitalize on diagnostic industry growth. The intraday rally reflects immediate investor optimism over the strategic collaboration, which aligns with Dyadic's focus on commercializing recombinant protein solutions.